1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Eisai completes acquisition of AkaRx

 
• By Ian Haydock

Eisai has completed the acquisition of AkaRx for $255 million, in a move which will give it sole worldwide rights to the US firm's thrombocytopenia drug AKR-501.

Eisai has completed the acquisition of AkaRx for $255 million, in a move which will give it sole worldwide rights to the US firm's thrombocytopenia drug AKR-501.

The transaction, first announced last month, was routed through the Japanese firm's US subsidiary, which now wholly owns New Jersey-based...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapeutic Category

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.